The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 4
  • 1
    Bond, John Matthew
    Chief Financial Officer born in March 1961
    Individual (1 offspring)
    Officer
    2023-08-18 ~ now
    OF - director → CIF 0
  • 2
    Mr Steven Bruce Klinsky
    Born in May 1956
    Individual (16 offsprings)
    Person with significant control
    2022-07-07 ~ now
    PE - Ownership of voting rights - 75% or more → CIF 0
  • 3
    Ronco, Peter
    Chief Executive Officer, The Emmes Company, Llc born in May 1972
    Individual (1 offspring)
    Officer
    2023-09-20 ~ now
    OF - director → CIF 0
  • 4
    Chilukuri, Sastry Venkata
    Executive Chairman, The Emmes Company, Llc. born in February 1975
    Individual (1 offspring)
    Officer
    2023-09-20 ~ now
    OF - director → CIF 0
Ceased 14
  • 1
    Ollier, Susan
    Clincial Research born in August 1955
    Individual (1 offspring)
    Officer
    2009-09-15 ~ 2014-02-19
    OF - director → CIF 0
  • 2
    Henry, Rhonda Usilton
    President, Emmes Biopharma born in May 1967
    Individual
    Officer
    2022-12-21 ~ 2023-08-15
    OF - director → CIF 0
  • 3
    Dingivan, Christine
    President And Ceo Of Emmes born in March 1967
    Individual
    Officer
    2022-12-21 ~ 2023-09-20
    OF - director → CIF 0
  • 4
    Marek, Pavel
    Managing Director born in March 1962
    Individual (1 offspring)
    Officer
    2022-12-21 ~ 2023-08-17
    OF - director → CIF 0
  • 5
    Ogorka, Nazira Khalid
    Director Clinical Operations & Global Partnering born in February 1968
    Individual (3 offsprings)
    Officer
    2012-11-01 ~ 2022-09-02
    OF - director → CIF 0
    Ogorka, Nazira Khalid
    Individual (3 offsprings)
    Officer
    2002-07-30 ~ 2008-03-31
    OF - secretary → CIF 0
    Mrs Nazira Ogorka
    Born in February 1968
    Individual (3 offsprings)
    Person with significant control
    2016-04-06 ~ 2021-05-11
    PE - Has significant influence or control → CIF 0
  • 6
    Vadodaria, Sheetal
    Individual (1 offspring)
    Officer
    2014-09-24 ~ 2022-12-22
    OF - secretary → CIF 0
  • 7
    Ogorka, Thomas
    Pharmaceutical born in June 1964
    Individual (3 offsprings)
    Officer
    2002-07-30 ~ 2022-12-22
    OF - director → CIF 0
    Mr Thomas Ogorka
    Born in June 1964
    Individual (3 offsprings)
    Person with significant control
    2016-04-06 ~ 2021-05-11
    PE - Ownership of shares – 75% or more → CIF 0
  • 8
    Budd, Wendy
    Individual
    Officer
    2012-03-01 ~ 2014-09-24
    OF - secretary → CIF 0
  • 9
    Decarlo, Jonathan Paul
    Chief Financial Officer born in January 1980
    Individual
    Officer
    2022-12-21 ~ 2023-06-30
    OF - director → CIF 0
  • 10
    Glickfield Bang, Debra
    Chief Legal Officer born in January 1963
    Individual
    Officer
    2022-03-07 ~ 2023-07-07
    OF - director → CIF 0
    Bang, Debra Glickfield
    Individual
    Officer
    2022-12-22 ~ 2023-07-07
    OF - secretary → CIF 0
  • 11
    Mangroo, Rajmattie Kumarie
    Individual (1 offspring)
    Officer
    2008-04-01 ~ 2012-02-29
    OF - secretary → CIF 0
  • 12
    Van Veldhuisen, Paul
    President, Emmes Public Sector born in November 1969
    Individual
    Officer
    2022-12-21 ~ 2023-08-15
    OF - director → CIF 0
  • 13
    Mellier House, 26a Albemarle Street, London
    Corporate (1 parent, 207 offsprings)
    Equity (Company account)
    1 GBP2023-12-31
    Officer
    2002-07-30 ~ 2002-07-30
    PE - nominee-secretary → CIF 0
  • 14
    C/o Ct Corporation System, 4701 Cox Road, Suite 285, Glen Allen, Postal Code 23060, Virginia, United States
    Corporate
    Person with significant control
    2021-05-11 ~ 2022-07-07
    PE - Ownership of shares – 75% or more → CIF 0
parent relation
Company in focus

EMMES BIOPHARMA UK LIMITED

Previous names
ORPHAN REACH LIMITED - 2023-01-05
QED CLINICAL SERVICES LIMITED - 2018-07-20
MONITORDIRECT LIMITED - 2002-10-01
Standard Industrial Classification
72190 - Other Research And Experimental Development On Natural Sciences And Engineering
Brief company account
Intangible Assets
239,327 GBP2023-12-31
283,325 GBP2022-12-31
Property, Plant & Equipment
5,196 GBP2023-12-31
13,647 GBP2022-12-31
Fixed Assets - Investments
421,756 GBP2023-12-31
450,451 GBP2022-12-31
Fixed Assets
666,279 GBP2023-12-31
747,423 GBP2022-12-31
Debtors
Current
14,334,472 GBP2023-12-31
10,982,365 GBP2022-12-31
Cash at bank and in hand
1,588,173 GBP2023-12-31
3,009,671 GBP2022-12-31
Current Assets
15,922,645 GBP2023-12-31
13,992,036 GBP2022-12-31
Net Current Assets/Liabilities
10,932,443 GBP2023-12-31
9,406,693 GBP2022-12-31
Total Assets Less Current Liabilities
11,598,722 GBP2023-12-31
10,154,116 GBP2022-12-31
Net Assets/Liabilities
11,524,479 GBP2023-12-31
10,079,873 GBP2022-12-31
Equity
Called up share capital
1,954 GBP2023-12-31
1,954 GBP2022-12-31
1,954 GBP2021-12-31
Share premium
97,805 GBP2023-12-31
97,805 GBP2022-12-31
97,805 GBP2021-12-31
Retained earnings (accumulated losses)
11,424,720 GBP2023-12-31
9,980,114 GBP2022-12-31
4,541,153 GBP2021-12-31
Equity
11,524,479 GBP2023-12-31
10,079,873 GBP2022-12-31
4,640,912 GBP2021-12-31
Profit/Loss
Retained earnings (accumulated losses)
1,444,606 GBP2023-01-01 ~ 2023-12-31
5,438,961 GBP2022-01-01 ~ 2022-12-31
Profit/Loss
1,444,606 GBP2023-01-01 ~ 2023-12-31
5,438,961 GBP2022-01-01 ~ 2022-12-31
Tax/Tax Credit on Profit or Loss on Ordinary Activities
460,092 GBP2023-01-01 ~ 2023-12-31
1,283,026 GBP2022-01-01 ~ 2022-12-31
Property, Plant & Equipment - Gross Cost
Land and buildings
86,639 GBP2022-12-31
Tools/Equipment for furniture and fittings
122 GBP2023-12-31
4,722 GBP2022-12-31
Other
10,963 GBP2023-12-31
37,642 GBP2022-12-31
Property, Plant & Equipment - Gross Cost
11,085 GBP2023-12-31
129,003 GBP2022-12-31
Property, Plant & Equipment - Disposals
Land and buildings
-86,639 GBP2023-01-01 ~ 2023-12-31
Tools/Equipment for furniture and fittings
-4,600 GBP2023-01-01 ~ 2023-12-31
Other
-30,416 GBP2023-01-01 ~ 2023-12-31
Property, Plant & Equipment - Disposals
-121,655 GBP2023-01-01 ~ 2023-12-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
Land and buildings
80,526 GBP2022-12-31
Tools/Equipment for furniture and fittings
122 GBP2023-12-31
3,246 GBP2022-12-31
Other
5,767 GBP2023-12-31
31,585 GBP2022-12-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
5,889 GBP2023-12-31
115,357 GBP2022-12-31
Property, Plant & Equipment - Increase From Depreciation Charge for Year
Land and buildings
5,059 GBP2023-01-01 ~ 2023-12-31
Tools/Equipment for furniture and fittings
321 GBP2023-01-01 ~ 2023-12-31
Other
4,310 GBP2023-01-01 ~ 2023-12-31
Property, Plant & Equipment - Increase From Depreciation Charge for Year
9,690 GBP2023-01-01 ~ 2023-12-31
Property, Plant & Equipment - Decrease in depreciation and impairment related to disposals
Land and buildings
-85,585 GBP2023-01-01 ~ 2023-12-31
Tools/Equipment for furniture and fittings
-3,445 GBP2023-01-01 ~ 2023-12-31
Other
-30,128 GBP2023-01-01 ~ 2023-12-31
Property, Plant & Equipment - Decrease in depreciation and impairment related to disposals
-119,158 GBP2023-01-01 ~ 2023-12-31
Property, Plant & Equipment
Other
5,196 GBP2023-12-31
6,058 GBP2022-12-31
Land and buildings
6,113 GBP2022-12-31
Tools/Equipment for furniture and fittings
1,476 GBP2022-12-31
Investments in Subsidiaries
421,756 GBP2023-12-31
450,451 GBP2022-12-31
Cost valuation
421,756 GBP2023-12-31
450,451 GBP2022-12-31
Trade Debtors/Trade Receivables
Current, Amounts falling due within one year
4,672,696 GBP2023-12-31
4,650,183 GBP2022-12-31
Debtors
Current, Amounts falling due within one year
14,334,472 GBP2023-12-31
10,982,365 GBP2022-12-31
Cash and Cash Equivalents
1,588,173 GBP2023-12-31
3,009,671 GBP2022-12-31
  • EMMES BIOPHARMA UK LIMITED
    Info
    ORPHAN REACH LIMITED - 2023-01-05
    QED CLINICAL SERVICES LIMITED - 2018-07-20
    MONITORDIRECT LIMITED - 2002-10-01
    Registered number 04498663
    Regus House Fairbourne Drive, Atterbury, Milton Keynes MK10 9RG
    Private Limited Company incorporated on 2002-07-30 (22 years 10 months). The company status is Active.
    The last date of confirmation statement was made at 2024-11-17
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.

qrcode

Privacy policy

© 2022-2025 Polylogarithmic Technology Ltd. All rights reserved.
Contains public sector information retrieved at 24 April 2025 and licensed under the Open Government Licence v3.0.